Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?

Oncology Reports

Volumn 23, Issue 2, 2010, Pages 471-475

  Funamizu, Naotake ^a   Okamoto, Aikou ^a   Kamata, Yuko ^a   Misawa, Takeyuki ^a   Uwagawa, Tadashi ^a   Gocho, Takeshi ^a   Yanaga, Katsuhiko ^a   Manome, Yoshinobu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Deoxycytidine deaminase; Deoxycytidine kinase; Gemcitabine; Pancreatic cancer; Tetra hydro uridine

Indexed keywords

DEOXYCYTIDINE KINASE; GEMCITABINE; TETRAHYDROURIDINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NUCLEOSIDE DEAMINASES; PANCREATIC NEOPLASMS; TETRAHYDROURIDINE; TRANSFECTION; UP-REGULATION;

EID: 76649097360     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000657     Document Type: Article

References (32)

1. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R and Mackey JR: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine treated pancreas adenocarcinoma. Clin Cancer Res 10: 6956-6961, 2004.
2. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A and Pastor-Anglada M: Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2,-difluorodeoxy-cytidine-induced cytotoxicity. Clin Cancer Res 9: 5000-5008, 2003.
3. Kroep JR, Loves WJ, van der Wilt CL, et al: Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1: 371-376, 2002.
4. Blackstock AW, Lightfoot H, Case LD, et al: Tumor uptake and elimination of 2′,2,-difluorodeoxy-cytidine (gemcitabine) after deoxycytidine kinase gene transfer correlation with in vivo tumor response. Clin Cancer Res 7: 3263-3268, 2001.
5. Neff T and Blau CA: Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 24: 1340-1346, 1996.
6. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B and Peters GJ: In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65: 9510-9516, 2005.
7. Nakahira S, Nakamori S, Tsujie M, et al: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120: 1355-1363, 2003.
8. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW and Fine HA: Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 2: 567-573, 1996.
9. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
10. Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR and Dumontet C: Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 24: 4-8, 2004.
11. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T and Ueda R: Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 95: 753-757, 2004.
12. Jordheim LP, Galmarini CM and Dumontet C: Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Cancer Chemother Pharmacol 58: 547-554, 2006.
13. Bengala C, Guarneri V, Giovannetti E, et al: Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer 93: 35-40, 2005.
14. Bouffard DY, Laliberté J and Momparler RL: Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45: 1857-1861, 1993.
15. Smid K, Bergman AM, Eijk PP, et al: Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids 25: 1001-1007, 2006.
16. Mori R, Ishikawa T and Ichikawa Y: Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 17: 1201-1205, 2007.
17. Giovannetti E, Del Tacca M, Mey V, et al: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66: 3928-3935, 2006.
18. Hubeek I, Stam RW, Peters GJ, et al: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 93: 1388-1394, 2005.
19. Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB and Cass CE: Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22: 7524-7536, 2003.
20. Mata JF, García-Manteiga JM, Lostao MP, et al: Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5(Prime)-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 59: 1542-1548, 2001.
21. Rauchwerger DR, Firby PS, Hedley DW and Moore MJ: Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 60: 6075-6079, 2000.
22. Matthews DJ, Yakes FM, Chen J, et al: Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6: 104-110, 2007.
23. Mey V, Giovannetti E, De Braud F, et al: In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 95: 289-297, 2006.
24. Hoffmann D and Wildner O: Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy. Mol Cancer Ther 5: 2013-2022, 2006.
25. Bianco C, Giovannetti E, Ciardiello F, et al: Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 12: 7099-7107, 2006.
26. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M and Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells. Mol Pharmacol 68: 110-118, 2005.
27. Vernejoul F, Ghénassia L, Souque A, et al: Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther 14: 758-767, 2006.
28. Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, Del Tacca M and Danesi R: Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93: 319-330, 2005.
29. Yao B, He QM, Tian L, et al: Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models. Hum Gene Ther 16: 1075-1086, 2005.
30. Hamada S, Satoh K, Kimura K, Kanno A, Masamune A and Shimosegawa T: MSX2 overexpression inhibits gemcitabine-induced caspase-3 activity in pancreatic cancer cells. World J Gastroenterol 11: 6867-6870, 2005.
31. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23: 1539-1548, 2004.
32. Kindler HL: The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer 95: 928-932, 2002.